Revolver Therapeutics, a University Bath spinout, is developing a revolutionary platform technology to fight against childhood cancer. They are 

discovering and developing constrained peptide drugs targeting transcription factors, which have traditionally been considered “undruggable.” The company aims to create potent functional and selective inhibitors of transcription factors to treat cancer and other diseases.

Their business model combines platform partnering and internal asset creation. The peptide therapeutics market is growing rapidly, with several competitors in the space having secured significant investments or partnerships recently. We believe its unique approach to screening functional inhibitors of transcription factors differentiates it from competitors and positions it well to address large unmet needs in cancer and other diseases.